Drug discovery in oncology is a competitive and fast moving field. As a highly ambitious company, we are interested in working with innovative industry partners and academic centers of excellence to progress the science and understanding of synthetic letality and to apply our innovative libraries and platforms in cancer biology, to discover novel mechanisms to induce cancer cell death, without harming healthy cells. This will enable us to develop breakthrough precision cancer therapies that are safer and more effective.